Ovid Therapeutics Inc. (OVID)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenue | 6,272 | 130 | 173 | 169 |
| Research and development | 6,465 | 6,659 | 7,855 | 12,582 |
| General and administrative | 4,880 | 6,021 | 5,544 | 8,104 |
| Total operating expenses | 11,345 | 12,680 | 13,399 | 20,686 |
| Loss from operations | -5,073 | -12,550 | -13,226 | -20,517 |
| Other income (expense), net | 389 | 2,315 | -780 | 29,038 |
| (loss) income before provision for income taxes | -4,684 | -10,235 | -14,006 | 8,521 |
| Provision for income taxes | - | - | - | - |
| Net (loss) income | -4,684 | -10,235 | -14,006 | 8,521 |
| Basic eps | - | -141.57 | -0.2 | 0.12 |
| Diluted eps | - | -141.57 | -0.2 | 0.12 |
| Basic average shares | - | 1,250 | 70,975,778 | 70,916,471 |
| Diluted average shares | - | 1,250 | 70,975,778 | 71,200,798 |